KF
NBIX icon

Krilogy Financial’s Neurocrine Biosciences NBIX Stock Holding History

Krilogy Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Sell
6,884
-1,656
-19% -$246K 0.03% 346
2026
Q1 		$1.1M Sell
8,540
-2,906
-25% -$386K 0.04% 343
2025
Q4 		$1.54M Buy
11,446
+3,157
+38% +$457K 0.05% 252
2025
Q3 		$1.27M Buy
+8,289
New +$1.12M 0.05% 280

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Krilogy Financial's NBIX Position: Q2 2026 in Review

Krilogy Financial reduced its Neurocrine Biosciences (NBIX) stake by 19% in Q2 2026, selling an estimated $246K and leaving 6,884 shares worth $1.16M. The position accounts for 0.03% of the portfolio, ranked #346.

Krilogy Financial first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.54M in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Krilogy Financial held 6,884 shares of Neurocrine Biosciences worth $1.16M as of Q2 2026.
  • Krilogy Financial sold 1,656 Neurocrine Biosciences shares in Q2 2026, an estimated $246K.
  • Neurocrine Biosciences made up 0.03% of Krilogy Financial's portfolio in Q2 2026, its #346 holding.
  • Krilogy Financial first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Krilogy Financial's Neurocrine Biosciences position peaked at $1.54M in Q4 2025.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.